3 Japanese AI Healthcare Stocks Backed By Real Software Adoption

Oil prices are feeding into inflation expectations again, which keeps pressure on healthcare systems to do more with tighter budgets. That is where transformative AI healthcare stocks come in. These companies aim to cut costs, speed up diagnosis, and support stretched workforces. This article highlights three stocks from the Transformative AI Healthcare screener that show how this theme is playing out in real businesses today.

The three stocks covered below are just a starting sample of this healthcare AI theme. The full screen surfaced three more companies with equally compelling narratives that are not discussed here. To identify your own highest conviction ideas, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

ASO International (TSE:9340)

Overview: ASO International is a Japan based specialist in dental orthodontics that provides a wide range of braces, clear aligners and custom devices, along with 3D printers, scanning tools and digital modeling services that help clinics move toward fully digital orthodontic workflows.

Market Cap: ¥6.9 billion

ASO International brings together clear aligners, lingual braces and in house 3D printing systems, which positions it at the heart of AI supported digital orthodontics. Earnings growth has been solid rather than explosive, yet the company is described as trading at good value, with a P/E that sits well below both peer and industry averages. Profit margins are in the low double digits and improving, which helps support planned dividend increases out to FY2027. The main red flags are a reliance on external borrowing for funding and a board with no independent directors. For investors tracking practical AI in healthcare, that mix of attractive valuation, growing digital services and governance and funding questions is exactly where deeper research can pay off.

ASO International’s low P/E and improving margins hint that the market may be underpricing its shift into AI supported digital orthodontics. Before you decide it is just another value trap, study the analysis report for ASO International

Build your own AI powered healthcare shortlist

ASO International and the two other stocks in this article all surfaced from a single Simply Wall St screen, but the real edge comes when you tailor the hunt yourself. Use our flexible Screener to mix valuation, growth, quality and dividend filters to suit your style, or lean on our curated Investing Ideas for ready made starting points.

eWeLLLtd (TSE:5038)

Overview: eWeLLLtd runs a suite of cloud tools for Japan’s home based nursing sector, including electronic medical records, insurance claim processing, attendance management, AI supported visit reporting, e learning and financing services that keep visiting nursing stations connected and compliant.

Operations: eWeLLLtd currently generates its ¥3.6 billion in revenue almost entirely from providing services to home visit nursing stations.

Market Cap: ¥32.0 billion

eWeLLLtd sits at the intersection of healthcare, software and AI, with its iBow platform and related services supporting every step of home based nursing, from charts and claims to AI assisted visit reports.

eWeLLLtd’s tightly focused ¥3.6b home nursing engine could be just the start, yet the real story sits inside the analyst forecasts for eWeLLLtd. The crucial question is how far that niche can stretch before competitive or regulatory friction bites.

FINDEX (TSE:3649)

Overview: FINDEX is a Japan based health IT company that builds software for hospitals and clinics, covering image and document management, electronic medical records, specialty tools for fields like ophthalmology and radiology, and AI supported medical text and workflow automation through products such as CocktailAI and DigiWorker.

Operations: FINDEX generates almost all of its roughly ¥6.1 billion in revenue from Japan, with about ¥5.8 billion coming from its core Medical Business and the rest from Health Tech and Public Sector services.

Market Cap: ¥21.6 billion

FINDEX stands out in this AI healthcare theme because it combines a long established medical software footprint with newer tools that apply generative AI and automation directly to clinical workflows. Forecast earnings growth of around 15% a year and a projected return on equity above 22% are presented alongside a share price that is described as below an estimated fair value based on future cash flows. At the same time, 100% reliance on external borrowing and a board that is only 36% independent keep governance and capital structure in focus. With Q2 2026 results due today, the next set of numbers could sharpen views on whether this mix of growth, quality earnings and AI products is being fully recognised.

FINDEX’s AI products sit on top of an established software base, which could make the analyst forecasts for FINDEX especially important for investors who want to see whether that earnings profile hides one crucial twist.

Seeking Alternatives Before The Crowd Moves

Fresh stock ideas do not stay quiet for long. Once momentum builds and prices start flying, the best entry points get caught quickly. Scan these curated screens while it matters and act now.

• Spot sturdy payers that can keep income flowing even when prices swing by scanning the curated 37 dividend fortresses before yields start dropping toward the crowd.
• Hunt for financially sound small companies in the AI space with the focused 11 AI small caps and reach them while they are still under the radar for now.
• Zero in on durable balance sheets and healthy cash flows using the hand picked list of solid balance sheet and fundamentals (41 results) before quality premiums widen and the easy bargains disappear.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com